The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
- 1 November 1998
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 52 (1-3) , 99-111
- https://doi.org/10.1023/a:1006115218786
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 WorkshopEuropean Journal Of Cancer, 1996
- Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissuesBreast Cancer Research and Treatment, 1996
- Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassayEuropean Journal Of Cancer, 1996
- Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancerInternational Journal of Cancer, 1995
- Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer PrognosisJournal of the American Statistical Association, 1992
- Integrating prognostic factorsBreast Cancer Research and Treatment, 1992
- Plasminogen activator system in human breast cancerInternational Journal of Cancer, 1992
- Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assayCancer Letters, 1991
- Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast CancerSeminars in Thrombosis and Hemostasis, 1991
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989